METHODS TO PREDICT CLINICAL OUTCOME OF CANCER
Granted: July 27, 2017
Application Number:
20170211154
The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer…
METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER
Granted: May 4, 2017
Application Number:
20170121780
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
METHOD OF PREDICTING BREAST CANCER PROGNOSIS
Granted: August 4, 2016
Application Number:
20160222463
The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
Granted: April 7, 2016
Application Number:
20160097105
Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER
Granted: February 18, 2016
Application Number:
20160048632
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the…
GENE FUSIONS AND ALTERNATIVELY SPLICED JUNCTIONS ASSOCIATED WITH BREAST CANCER
Granted: October 22, 2015
Application Number:
20150302143
The present invention relates to gene fusions and alternative spliced junctions associated with breast cancer. The present invention also relates to novel methods of identifying gene fusions and alternative spliced junctions in RNA sequencing data. The present invention further relates to predicting prognosis of a breast cancer patient based on the number of gene fusion events.
METHODS FOR DEPLETING RNA FROM NUCLEIC ACID SAMPLES
Granted: October 22, 2015
Application Number:
20150299771
The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer
Granted: October 9, 2014
Application Number:
20140303002
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
METHOD OF PREDICTING BREAST CANCER PROGNOSIS
Granted: October 2, 2014
Application Number:
20140296085
The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
GENE EXPRESSION MARKERS FOR BREAST CANCER PROGNOSIS
Granted: September 25, 2014
Application Number:
20140287421
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY
Granted: July 24, 2014
Application Number:
20140206545
The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant…
GENE EXPRESSION MARKERS FOR PREDICTION OF RESPONSE TO PHOSPHOINOSITIDE 3-KINASE INHIBITORS
Granted: October 17, 2013
Application Number:
20130274127
The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene…
Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer
Granted: August 1, 2013
Application Number:
20130196321
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
GENE EXPRESSION MARKERS FOR COLORECTAL CANCER PROGNOSIS
Granted: April 25, 2013
Application Number:
20130102492
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
PREDICTORS OF PATIENT RESPONSE TO TREATMENT WITH EGF RECEPTOR INHIBITORS
Granted: October 25, 2012
Application Number:
20120270228
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
Gene expression markers for prediction of patient response to chemotherapy
Granted: October 15, 2009
Application Number:
20090258795
A method of predicting clinical outcome in a subject diagnosed with cancer and treated with chemotherapy comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample comprising cancer cells obtained from the subject.
Method for quantitative PCR data analysis system (QDAS)
Granted: January 12, 2006
Application Number:
20060008809
This invention provides a method for the quantitation and quality assurance of QPCR data. In particular, the invention provides a method for extracting data curves from a QPCR assay, estimating the shape and characteristics of an amplification curve and producing a quality score metric. The invention also provides a robust method for calculating a threshold cycle (CT) value and classifying the status of the QPCR results.
Gene expression markers for predicting response to chemotherapy
Granted: November 24, 2005
Application Number:
20050260646
The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1;…
qRT-PCR assay system for gene expression profiling
Granted: May 5, 2005
Application Number:
20050095634
The invention concerns an integrated, qRT-PCR-based system for analyzing and reporting RNA expression profiles of biological samples. In particular, the invention concerns a fully optimized and integrated multiplex, multi-analyte method for expression profiling of RNA in biological samples, including fixed, paraffin-embedded tissue samples. The gene expression profiles obtained can be used for the clinical diagnosis, classification and prognosis of various pathological conditions,…
Genomic profile information systems and methods
Granted: July 18, 2002
Application Number:
20020095585
A variety of methods and systems related to genomic profile information and related participants are described. Participants can be encouraged to allow access to their genomic profile information in a variety of ways. A peer-to-peer genomic profile information network can be implemented. A collection of genomic profile information for a large number of participants can be built, and anonymity of the participants can be maintained. Participants can maintain custodial control over their…
